Introduction
============

The mechanisms underlying lung cancer pathogenesis and progression remain under investigation. Ground-glass opacity (GGO) lesions, increasingly detected by computed tomography (CT) scanning, can be classified as adenomatous hyperplasia (AAH), bronchioalveolar carcinoma (BAC) or adenocarcinoma (AC). Several studies have suggested that AAH, frequently found in tissue surrounding lung AC, might be a forerunner in the development of AC. Moreover, an increasing genetic complexity associated with lung cancer progression has been demonstrated by means of loss of heterozygosity, fluorescence in situ hybridization, microarrays and immunohistochemistry but the clonal association between AAH, BAC and AC continue to be debated ([@b1-etm-0-0-2870]--[@b7-etm-0-0-2870]).

In the present study the array-comparative genomic hybridization (a-CGH) technique was applied on three DNA samples from a patient presenting AAH, BAC and AC in one lung, in order to confirm the previous cytogenetic data for that patient ([@b8-etm-0-0-2870]), suggesting a clonal evolution of these lesions and the pre-neoplastic nature of AAH.

Case report
===========

A 54-year-old female patient who had never smoked was diagnosed by CT scan at the Humanitas Clinical and Research Center (Milan, Italy) with a lung tumor in the upper right lobe and a GGO in the lower lobe, while the middle lobe appeared to be normal. Written informed consent was obtained from the patient. Histological evaluation lead to a diagnosis of AC with a BAC component in the upper right lobe, BAC in the inferior lobe and AAH in the middle lobe. Following pneumonectomy, a cytogenetic investigation of spontaneous metaphases obtained using a direct method from the three different samples was performed, as previously reported ([@b8-etm-0-0-2870],[@b9-etm-0-0-2870]). The karyotypes showed a clear clonal association among AC, BAC and AAH ([@b8-etm-0-0-2870]).

An a-CGH study was performed on the DNA isolated from the three lung samples and stored at −20°C using the Qiagen DNeasy Blood & Tissue kit (Qiagen Inc., Valencia, CA, USA). The samples were then processed using a SurePrint G3 Cancer CGH+SNP 4×180 K microarray kit (Agilent Technologies, Inc., Santa Clara, CA, USA) according to the manufacturer\'s instructions. Results were analyzed according to Human Genome version 19 (Hg19) ([@b10-etm-0-0-2870]). The data obtained from the a-CGH study confirmed the hypothesis of multistep progression of the lung cancer that was previously made on the basis of the previously reported, limited cytogenetic results ([@b8-etm-0-0-2870]). The three different lesions shared losses in 1p, 4p, 9q, 11p, 12p, 14q, 15q, 16p, 16q and 22q ([Table I](#tI-etm-0-0-2870){ref-type="table"}). The common minimal regions of deletions included genes with an established role in lung cancer that regulate the cell cycle or are involved in the maintenance of chromosomal stability and DNA repair ([@b10-etm-0-0-2870]--[@b14-etm-0-0-2870]). The most relevant genes included in the deleted regions are listed in [Table I](#tI-etm-0-0-2870){ref-type="table"}. The data obtained support the hypothesis suggested by Bettio *et al* concerning the loss of the cell cycle control in the AAH sample in which actively replicating cells with a normal karyotype were observed ([@b8-etm-0-0-2870]).

In addition to the aforementioned abnormalities, the BAC and AC samples showed gain in 1q, loss in 17q, trisomy 7, monosomy 9 and monosomy 22. Notably, these chromosome imbalances involved genes that have previously been demonstrated to play a crucial role in lung cancer ([Table I](#tI-etm-0-0-2870){ref-type="table"}) ([@b10-etm-0-0-2870],[@b11-etm-0-0-2870],[@b15-etm-0-0-2870]--[@b20-etm-0-0-2870]).

Additional alterations were observed only in the AC specimen: Loss in 12q, 20p and 20q, loss of the entire 16p arm and chromosome 17 and 19 monosomy. These regions include genes reported to be frequently deleted in lung neoplasia ([Table I](#tI-etm-0-0-2870){ref-type="table"}) ([@b10-etm-0-0-2870],[@b11-etm-0-0-2870],[@b21-etm-0-0-2870]--[@b24-etm-0-0-2870]).

Discussion
==========

The pathogenesis of lung cancer and the criteria that regulate its progression are not well understood. Several studies have suggested that AAH, frequently found in tissue surrounding lung AC, may be a forerunner in its development but the genetic relationship between these two entities is not yet defined ([@b4-etm-0-0-2870],[@b25-etm-0-0-2870]--[@b27-etm-0-0-2870]). The present case lends itself well to the investigation of the multistep carcinogenesis hypothesis of the lung because of the presence of three different lesions in the three lobes of the same lung. The a-CGH technique was applied in order to confirm the previous cytogenetic observations that were limited by the low proliferation rate of the tumor cells, and the poor resolution and incompleteness of metaphase spreads, which allowed the identification of only a few clonal aberrations. Moreover the a-CGH analysis allowed a more detailed characterization of the genomic imbalances present in the three lesions. The data appear to support the pre-neoplastic nature of the AAH lesion that presented several genetic alterations shared with the BAC and AC samples. The chromosomal regions showing recurring imbalances encompass genes with already demonstrated critical roles in lung cancer development and progression: Tumor suppressor genes, genes controlling the cell cycle, differentiation and apoptosis ([@b10-etm-0-0-2870]--[@b24-etm-0-0-2870]). The presence of chromosome abnormalities shared by all the samples and the increase in the number of rearrangements and percentage of altered cells from AAH through BAC to AC clearly correlate with a clonal evolution confirming the multi-step process in lung cancer.

###### 

Genetic aberrations detected using CGH and SNP microarray analysis in the AAH, BAC and AC samples with the most relevant genes involved in lung tumorigenesis and the percentage of altered cells.

  Chromosome imbalances                    Size (Mb)   Genes                                                                                                                                           AAH (%)   BAC (%)   AC (%)
  ---------------------------------------- ----------- ----------------------------------------------------------------------------------------------------------------------------------------------- --------- --------- --------
  del([@b1-etm-0-0-2870])(p32.3p36.31)       47.5      NBL1-EPHB2-RUNX3-MYCL1-RLF-STIL-CDKN2C-ESP15-ERRFI1-YBX1-BMP8B-COL9A2-PPT1-ZMPSTE24-PPIE-CAP1-HEYL-HPCAL4-TRIT1-OXCT2-NT5C1A-MFSD2-TMCO2-YRDC   15        25        40
  del([@b4-etm-0-0-2870])(p14)                 2.1     --                                                                                                                                              30        30        50
  del([@b9-etm-0-0-2870])(q31.3q32)            2.0     RGS3-POL3                                                                                                                                       20        50        70
  del([@b11-etm-0-0-2870])(p15.4)              1.9     STK33-AKIP1-WEE1                                                                                                                                25        25        30
  del([@b12-etm-0-0-2870])(p11.21)             1.8     --                                                                                                                                              30        25        50
  del([@b14-etm-0-0-2870])(q13.1q13.2)         1.1     SNX6                                                                                                                                            30        30        50
  del([@b15-etm-0-0-2870])(q15.1q21.1)         5.7     BUB1B-CASC5-TP53BP1                                                                                                                             20        20        40
  del([@b15-etm-0-0-2870])(q26.1)              1.9     CRTC3-MFGE8-IQGAP1-FANCI                                                                                                                        20        20        35
  del([@b16-etm-0-0-2870])(p11.2)              1.7     --                                                                                                                                              50        50        60
  del([@b16-etm-0-0-2870])(q21q22.2)           9.0     CBFB-CDH1                                                                                                                                       25        25        35
  del([@b22-etm-0-0-2870])(q13.1q13.2)         2.7     EP300                                                                                                                                           20        45        60
  dup([@b1-etm-0-0-2870])(q23.1q43)          82.0      PRDX6-MUC1-PRCC-NTRK1-SDHC-LAMC2-CD73-MDM4-PTPN14-TGFB2-AKT3-ARNT-LAMB3                                                                         --        60        60
  Trisomy 7                                159.0       EGFR-DLX5-TWIST1-SEC61G-VSTM2A-TAC1                                                                                                             --        30        70
  Monosomy 9                               139.3       CDKN2A-CDKN2B-TOPORS-DMRTA1-JAK2-MTAP-XPA-SET-FNBP1-NOTCH1                                                                                      --        30        40
  del([@b17-etm-0-0-2870])(q21.2q21.33)        9.2     ETV4-NR1D1-RARA-TOP2A-BRCA1                                                                                                                     --        20        35
  Monosomy 22                                50.9      NF2-CHEK2-SET5-SMARCB1-EWSR1-ARHGAP8                                                                                                            --        30        40
  del([@b12-etm-0-0-2870])(q12q13.3)         12.3      WNT1-ATF1-CDK2-ERBB3                                                                                                                            --        --        30
  del([@b12-etm-0-0-2870])(q21.33q24.32)     34.1      BTG1-PTPN11                                                                                                                                     --        --        30
  del([@b16-etm-0-0-2870])(p11.2pter)        34.0      CIITA-SOCS1-TNRSF17-ABCC1-PALB2-IL21R-FUS                                                                                                       --        --        30
  Monosomy 17                                80.7      TP53-NF1-TOP2A-HLF-ERBB2-SOX9-CBX2                                                                                                              --        --        30
  Monosomy 19                                58.6      STK11-CXCL17-CCNE1-C19orf12-LTBP4-NUMBL-SPTBN4-ADCK4-ITPKC-SHKBP1                                                                               --        --        30
  del([@b20-etm-0-0-2870])(p12p13)             4.0     RASSF2                                                                                                                                          --        --        30
  del([@b20-etm-0-0-2870])(q12.2q13.33)      23.7      E2F1-SRC-MYBL2-ZNF217-TOP1-CSE1L-BCL2L1-TPX2                                                                                                    --        --        30

CGH, compative genomic hybridization; SNP, single-nucleotide polymorphism; AAH, adenomatous hyperplasia; BAC, bronchoalveolar carcinoma; AC, adenocarcinoma; del, loss of one copy; dup, gain of one copy.
